Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

被引:165
|
作者
Bhagwat, Shripad V. [1 ]
Gokhale, Prafulla C. [3 ]
Crew, Andrew P. [2 ]
Cooke, Andy [3 ]
Yao, Yan
Mantis, Christine [3 ]
Kahler, Jennifer
Workman, Jennifer [3 ]
Bittner, Mark [3 ]
Dudkin, Lorina [4 ]
Epstein, David M.
Gibson, Neil W.
Wild, Robert [3 ]
Arnold, Lee D. [2 ]
Houghton, Peter J. [4 ]
Pachter, Jonathan A.
机构
[1] OSI Pharmaceut Inc, Biochem & Cellular Pharmacol, Canc Biol, Farmingdale, NY 11735 USA
[2] OSI Pharmaceut Inc, Canc Chem, Farmingdale, NY 11735 USA
[3] OSI Pharmaceut Inc, Vivo Pharmacol, Boulder, CO USA
[4] Nationwide Childrens Hosp, Ctr Childhood Canc, Columbus, OH USA
关键词
MAMMALIAN TARGET; KINASE INHIBITOR; IN-VITRO; GROWTH; AUTOPHAGY; THERAPY; RICTOR; ROLES;
D O I
10.1158/1535-7163.MCT-10-1099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR is a clinically validated target. mTOR forms two distinct multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, metabolism, proliferation, and survival. Rapamycin and its analogues partially inhibit mTOR through allosteric binding to mTORC1, but not mTORC2, and have shown clinical utility in certain cancers. Here, we report the preclinical characterization of OSI-027, a selective and potent dual inhibitor of mTORC1 and mTORC2 with biochemical IC50 values of 22 nmol/L and 65 nmol/L, respectively. OSI-027 shows more than 100-fold selectivity for mTOR relative to PI3K alpha, PI3K beta, PI3K gamma, and DNA-PK. OSI-027 inhibits phosphorylation of the mTORC1 substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate AKT in diverse cancer models in vitro and in vivo. OSI-027 and OXA-01 (close analogue of OSI-027) potently inhibit proliferation of several rapamycin-sensitive and -insensitive nonengineered and engineered cancer cell lines and also, induce cell death in tumor cell lines with activated PI3K-AKT signaling. OSI-027 shows concentration-dependent pharmacodynamic effects on phosphorylation of 4E-BP1 and AKT in tumor tissue with resulting tumor growth inhibition. OSI-027 shows robust antitumor activity in several different human xenograft models representing various histologies. Furthermore, in COLO 205 and GEO colon cancer xenograft models, OSI-027 shows superior efficacy compared with rapamycin. Our results further support the important role of mTOR as a driver of tumor growth and establish OSI-027 as a potent anticancer agent. OSI-027 is currently in phase I clinical trials in cancer patients. Mol Cancer Ther; 10(8); 1394-406. (C) 2011 AACR.
引用
收藏
页码:1394 / 1406
页数:13
相关论文
共 50 条
  • [1] The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2
    Chen, Bo
    Xu, Ming
    Zhang, Hui
    Xu, Ming-zheng
    Wang, Xu-jing
    Tang, Qing-he
    Tang, Jian-ying
    DNA AND CELL BIOLOGY, 2015, 34 (10) : 610 - 617
  • [2] OSI-027, a dual mTORC1/mTORC2 inhibitor, induces autophagy in cancer cells
    O'Connor, Matthew
    Mohan, Amrita
    Brady, Suzanne
    Mantis, Christine
    Gokhale, Prafulla C.
    Miglarese, Mark R.
    Barr, Sharon M.
    CANCER RESEARCH, 2011, 71
  • [3] Discovery of OSI-027: An imidazotriazine-based orally efficacious dual inhibitor of mTORC1 and mTORC2
    Dong, Hanqing
    Bhagwat, Shripad V.
    Beard, David
    Bharadwaj, Apoorba
    Bittner, Mark A.
    Chen, Xin
    Coate, Heather
    Cooke, Andrew
    Gokhale, Prafulla
    Kahler, Jennifer
    Mantis, Christine
    Mulvihill, Mark J.
    Panicker, Bijoy
    Tavares-Greco, Paula A.
    Volk, Brian
    Wang, Jing
    Werner, Douglas S.
    Yao, Yan
    Arnold, Lee D.
    Pachter, Jonathan A.
    Wild, Robert
    Epstein, David
    Crew, Andrew P.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [4] A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
    Joaquin Mateo
    David Olmos
    Herlinde Dumez
    Srinivasu Poondru
    Nancy L Samberg
    Sharon Barr
    Jan M Van Tornout
    Fei Jie
    Shahneen Sandhu
    Daniel S Tan
    Victor Moreno
    Patricia M LoRusso
    Stan B Kaye
    Patrick Schöffski
    British Journal of Cancer, 2016, 114 : 889 - 896
  • [5] A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
    Mateo, Joaquin
    Olmos, David
    Dumez, Herlinde
    Poondru, Srinivasu
    Samberg, Nancy L.
    Barr, Sharon
    Van Tornout, Jan M.
    Jie, Fei
    Sandhu, Shahneen
    Tan, Daniel S.
    Moreno, Victor
    LoRusso, Patricia M.
    Kaye, Stan B.
    Schoffski, Patrick
    BRITISH JOURNAL OF CANCER, 2016, 114 (08) : 889 - 896
  • [6] Characterization of AZD8055, a potent selective inhibitor of mTORC1 and mTORC2 kinase
    Chresta, Christine
    Davies, Barry
    Harding, Tom
    Hickson, Ian
    Cosulich, Sabina
    Critchlow, Susan
    Sini, Patrizia
    James, Dominic
    Malagu, Karine
    Hummersone, Marc
    Smith, Graeme
    Pass, Martin
    Guichard, Sylvie
    CANCER RESEARCH, 2009, 69
  • [7] Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study.
    Mateo, Joaquin
    Schoffski, Patrick
    Olmos, David
    Dumez, Herlinde
    Moreno, Victor
    Jie, Fei
    Poondru, Srinivasu
    Samberg, Nancy L.
    Van Tornout, Jan M.
    Kaye, Stanley B.
    LoRusso, Patricia M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [8] Final results of a first-in-human clinical trial of OSI-027, a small molecule dual mTORC1/mTORC2 inhibitor in patients with advanced malignancies
    Schoffski, P.
    Mateo, J.
    Olmos, D.
    Barr, S.
    Poondru, S.
    Van Tornout, J.
    Dumez, H.
    LoRusso, P. M.
    Kaye, S. B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S162 - S163
  • [9] Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes
    Chen, Jun
    Liu, Ke
    Liu, Yang
    Wang, Xue
    Zhang, Zhen
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : 270 - 275
  • [10] Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2
    Pike, Kurt G.
    Morris, Jeff
    Ruston, Linette
    Pass, Sarah L.
    Greenwood, Ryan
    Williams, Emma J.
    Demeritt, Julie
    Culshaw, Janet D.
    Gill, Kristy
    Pass, Martin
    Finlay, M. Raymond V.
    Good, Catherine J.
    Roberts, Craig A.
    Currie, Gordon S.
    Blades, Kevin
    Eden, Jonathan M.
    Pearson, Stuart E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (05) : 2326 - 2349